Kazia Therapeutics Ltd 6-K, filed Jun 5, 2023
Kazia Therapeutics Ltd (KZIA)
About this 6-K
Kazia Therapeutics Ltd filed this 6-K on June 5, 2023.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of June, 2023
Commission File Number 000-29962
Kazia Therapeutics Limited
(Translation of registrant’s name into English)
Three International Towers Level 24 300 Barangaroo Avenue Sydney NSW 2000
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
INFORMATION CONTAINED IN THIS FORM 6-K REPORT
Appointment of Director
On June 5, 2023, the Board of Directors (the “Board”) of Kazia Therapeutics Limited (the “Company”) appointed Ms. Ebru Davidson as a director of the Company, effective June 5, 2023. The appointment intends to fill the vacancy created by Dr. James Garner’s departure. The biographical information of Ms. Davidson is set forth below.
Ms. Davidson is an experienced corporate lawyer and is currently the General Counsel for QBiotics Group Limited, an unlisted public Australian life sciences company that discovers and develops pharmaceuticals derived from nature to address unmet medical needs in humans and companion animals. As a former partner at Thomson Geer Lawyers, Ms. Davidson brings over 14 years’ experience in equity capital markets, private and public mergers and acquisitions, corporate transactions and corporate governance. She also has extensive experience in advising listed and unlisted entities on compliance and regulatory matters working closely with the Australian Securities and Investment Commission and Australian Securities Exchange.
Ms. Davidson holds a Bachelor of Science degree from the University of Melbourne, a Juris Doctor (Honours) from Bond University. Ms. Davidson is an Associate Member of the Governance Institute of Australia having completed a Graduate Diploma of Applied Corporate Governance.
On June 5, 2023, the Company issued an ASX announcement titled, “Kazia Expands Board of Directors with Appointment of Ebru Davidson.” A copy of this release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
The Company hereby incorporates by reference the information contained herein, including Exhibit 99.1, except for the quotes of Iain Ross in Exhibit 99.1, into the Company’s registration statement on Form F-3 (File No. 333-259224).
EXHIBIT LIST
| Exhibit | Description | |
| 99.1 | ASX Announcement of Kazia Therapeutics Limited dated June 5, 2023 | |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Kazia Therapeutics Limited (Registrant)
/s/ Karen Krumeich
Karen Krumeich
Chief Financial Officer
Date: 5 June 2023
Exhibit 99.1
ASX ANNOUNCEMENT
5 June 2023
KAZIA EXPANDS BOARD OF DIRECTORS WITH APPOINTMENT OF EBRU DAVIDSON
Ms Ebru Davidson appointed as a Non-Executive Director
Sydney, 5th June 2023 – Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, announced that Ms Ebru Davidson has been appointed to the Board of Kazia effective today.
Kazia’s Chairman, Iain Ross said:
“We are delighted Ebru has agreed to join the Kazia Board. As part of its ongoing renewal and succession planning, the Board is committed to ensuring an appropriate mix of skills, knowledge, and diversity. Ms. Davidson’s extensive expertise and ability to provide sound governance insights on corporate legal strategy and risk management will further strengthen and complement the current Board members.”
Ebru is a highly experienced corporate lawyer and is currently the General Counsel for QBiotics Group Limited, an unlisted public Australian life sciences company that discovers and develops pharmaceuticals derived from nature to address unmet medical needs in humans and companion animals. As a former partner at Thomson Geer Lawyers, Ebru brings over 14 years’ experience in equity capital markets, private and public mergers and acquisitions, corporate transactions and corporate governance. She also has extensive experience in advising listed and unlisted entities on compliance and regulatory matters working closely with the Australian Securities and Investment Commission and Australian Securities Exchange.
Ms. Davidson holds a Bachelor of Science degree from the University of Melbourne, a Juris Doctor (Honours) from Bond University. Ebru is an Associate Member of the Governance Institute of Australia having completed a Graduate Diploma of Applied Corporate Governance.
Ebru’s Appendix 3X (Initial Director’s Interest Notice) is attached to this announcement.
Media Enquiries
Jane Lowe
IR Department
Tel: +61 411 117 774
Email: jane.lowe@irdepartment.com.au
About Kazia Therapeutics Limited
Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA) is an oncology-focused drug development company, based in Sydney, Australia.
Our lead program is paxalisib, a brain-penetrant inhibitor of the PI3K / Akt / mTOR pathway, which is being developed to treat multiple forms of brain cancer. Licensed from Genentech in late 2016, paxalisib is or has been the subject of ten clinical trials in this disease. A completed phase II study in glioblastoma reported promising signals of efficacy in 2021, and a pivotal study for registration, GBM AGILE, is ongoing, with final data expected in CY2023. Other clinical trials are ongoing in brain metastases, diffuse midline gliomas, and primary CNS lymphoma, with several of these having reported encouraging interim data.
Paxalisib was granted Orphan Drug Designation for glioblastoma by the US FDA in February 2018, and Fast Track Designation for glioblastoma by the US FDA in August 2020. In addition, paxalisib was granted Rare Pediatric Disease Designation and Orphan Designation by the US FDA for DIPG in August 2020, and for atypical teratoid / rhabdoid tumours (AT/RT) in June 2022 and July 2022, respectively.
Kazia is also developing EVT801, a small-molecule inhibitor of VEGFR3, which was licensed from Evotec SE in April 2021. Preclinical data has shown EVT801 to be active against a broad range of tumour types and has provided compelling evidence of synergy with immuno-oncology agents. A phase I study commenced recruitment in November 2021.
For more information, please visit www.kaziatherapeutics.com or follow us on Twitter @KaziaTx.
This document was authorized for release to the ASX by Iain Ross, Chairman & Director.
Forward-Looking Statements
This announcement may contain forward-looking statements, which can generally be identified as such by the use of words such as “may,” “will,” “estimate,” “future,” “forward,” “anticipate,” or other similar words. Any statement describing Kazia’s future plans, strategies, intentions, expectations, objectives, goals or prospects, and other statements that are not historical facts, are also forward-looking statements, including, but not limited to, statements regarding: the timing for results and data related to Kazia’s clinical and preclinical trials, and Kazia’s strategy and plans with respect to its programs, including paxalisib. Such statements are based on Kazia’s expectations and projections about future events and future trends affecting its business and are subject to certain risks and uncertainties that could cause actual results to differ materially from those anticipated in the forward-looking statements, including risks and uncertainties: associated with clinical and preclinical trials and product development, related to regulatory approvals, risks related to Kazia’s executive leadership changes, and the related to the impact of global economic conditions, including disruptions in the banking industry. These and other risks and uncertainties are described more fully in Kazia’s Annual Report, filed on form 20-F with the SEC, and in subsequent filings with the SEC. Kazia undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise, except as required under applicable law. You should not place undue reliance on these forward-looking statements, which apply only as of the date of this announcement.
Appendix 3X
Initial Director’s Interest Notice
Rule 3.19A.1
Appendix 3X
Initial Director’s Interest Notice
Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.
Introduced 30/9/2001.
| Name of entity: Kazia Therapeutics Limited (ASX: KZA) |
| ACN: 063 259 754 |
We (the entity) give ASX the following information under listing rule 3.19A.1 and as agent for the director for the purposes of section 205G of the Corporations Act.
| Name of Director | Ebru Davidson | |
| Date of appointment | 5 June 2023 |
Part 1—Director’s relevant interests in securities of which the director is the registered holder
In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust
Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.
Number & class of securities
Nil
| + See chapter 19 for defined terms. | ||
| 11/3/2002 | Appendix 3X Page 1 |
Appendix 3X
Initial Director’s Interest Notice
Part 2 – Director’s relevant interests in securities of which the director is not the registered holder
In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust
| Name of holder & nature of interest
Note: Provide details of the circumstances giving rise to the relevant interest.
N/A
|
Number & class of Securities
Nil |
Part 3 – Director’s interests in contracts
Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.
| Detail of contract
|
N/A | |
| Nature of interest
|
||
| Name of registered holder (if issued securities)
|
||
| No. and class of securities to which interest relates
|
| + See chapter 19 for defined terms. | ||
| Appendix 3X Page 2 | 11/3/2002 |